ClinicalTrials.gg
Enrolling by invitationNCT05645224Updated Aug 27, 2026

VR-PAT for Pain and Anxiety Management During Pediatric Dermatologic Laser Procedures

An interventional study of VR-PAT in Procedural Anxiety and Procedural Pain, sponsored by Nationwide Children's Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 5 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Nationwide Children's Hospital · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
5 Years to 25 Years
Sex
All
01

Study summary

This study will assess the feasibility and efficacy of our Virtual Reality Pain Alleviation Therapy (VR-PAT) for pain management during pediatric and young adult outpatient laser procedures and evaluate the impact of VR use on reducing anxiety in patients undergoing dermatologic laser procedures. The investigators hypothesize that patients using VR-PAT will report less pain and anxiety during the laser procedure than patients who do not play the game.

Read the detailed description

In this three-group crossover randomized clinical trial, patients will be randomly assigned to either the VR-PAT intervention group, control group (same VR google without game), or standard of care at the first laser procedure and will then cross-over to the alternative group for the second laser procedure. Survey questions to assess pain and anxiety and control for confounding factors will be asked before and after each procedure. VR versus Control and VR versus Standard of Care will be compared.

02

Conditions studied

  • Procedural Anxiety
  • Procedural Pain

Browse trials for

Keywords

  • Laser
  • Dermatology
  • Virtual Reality
  • VR
03

In context

Pain, Procedural

241 studies on the registry are indexed under Pain, Procedural; 64 are open to participants now.

This study's planned enrollment of 65 is below the median of 90 across 227 interventional studies indexed under Pain, Procedural.

Browse Pain, Procedural studies →

Lead sponsor

Nationwide Children's Hospital is the lead sponsor of 233 studies on the registry; 43 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 9 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • dermatology patients (5+ years) who are undergoing first laser procedure at the Nationwide Children's Outpatient Laser
  • have a legal guardian present for patients less than 18 years old for the procedure (for )
  • can communicate orally

Exclusion criteria

Exclusion Criteria:

  • any wounds that may interfere with study procedures
  • usage of a diode laser (VR safety has not been established yet)
  • vision, hearing, or cognitive/motor impairments preventing valid administration of study measures
  • history of motion sickness, seizure disorder, dizziness, or migraine headaches precipitated by visual auras
  • minors in foster care
  • unable to communicate in English
  • pregnant women
  • prisoners
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    VR-PAT

    Participant wears the Pico Neo 3 Pro Eye headset and actively plays the VR-PAT game.

    Other: VR-PAT

  • No intervention
    Control

    Participant wears the Pico Neo 3 Pro Eye headset to protect eyes, but it is not turned on.

  • No intervention
    Standard of Care

    This will be a standard of care group that will match the current clinic practices. Subjects will wear the standard protective eyewear and offered current distraction options.

Interventions

  • OtherVR-PAT

    Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device

06

What researchers measure

Primary outcomes

  1. Change in procedural pain

    0-10 Numerical Rating Scale (NRS) (self-reported and caregiver-reported (if \<18 years)), 0(min)-10(max), with higher score indicating worse pain. Asked for worst pain, average pain, and time spent thinking about pain.

    Time frame: Assessed immediately following each laser procedure

  2. Change in procedural anxiety

    Modified Yale Preoperative Anxiety Scale (mYPAS) (observed by researcher), 23.33(min)-100(max), with higher scores denoting higher levels of anxiety.

    Time frame: Assessed at 3 time points (prior to entering procedure room, prior to the procedure, and immediately following the procedure) for each laser procedure

Secondary outcomes

  1. Self-reported VR experience

    0-10 Numerical Rating Scale (NRS) (self-reported - VR-PAT arm only), 0(min)-10(max), with higher score meaning better outcome. Asked for degree of realism, pleasure, and satisfaction with VR.

    Time frame: Immediately following laser procedure in VR-PAT group

  2. Nurse-reported utility

    Binary (Yes/No) questions of whether the nurse found VR-PAT to be helpful and easy to use during the procedure.

    Time frame: Immediately following laser procedure in VR-PAT group

07

Study locations

1 site
08

References and documents

Publications

  • Armstrong M, Williams H, Fernandez Faith E, Ni A, Xiang H. Virtual Reality for Pain Management During Repeated Pediatric Laser Procedures: Protocol for a Pilot Randomized Clinical Trial. JMIR Res Protoc. 2026 Jun 9;15:e87207. doi: 10.2196/87207. PubMed 42263172 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Nov 2025, 34 months.

Of 141 non-industry interventional studies with no phase under Pain, Procedural, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's 34 months is above that.

Counting every sponsor, half of 141 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 9, 2022
StartActual
Jan 9, 2023
Primary completionActual
Nov 14, 2025
CompletionEst.
Dec 31, 2027
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05645224
Responsible party
Henry Xiang (Professor of Medicine and Center Director, Nationwide Children's Hospital) — Principal investigator
First posted
Dec 9, 2022
Start date
Jan 9, 2023
Primary completion
Nov 14, 2025
Completion
Dec 31, 2027 (estimated)
Last update
Aug 27, 2026

Study contacts

Henry Xiang, MD, MPH, PhD, MBA
principal investigator · Nationwide Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion